Lilly, Vir Biotechnology and GSK Announce First Patient Dosed in Expanded BLAZE-4 Trial Evaluating Bamlanivimab (LY-CoV555) with VIR-7831 (GSK4182136) for COVID-19
January 27, 2021 06:45 ET
|
Vir Biotechnology, Inc.
INDIANAPOLIS, SAN FRANCISCO and LONDON, Jan. 27, 2021 (GLOBE NEWSWIRE) -- Eli Lilly and Company (NYSE: LLY), Vir Biotechnology, Inc. (NASDAQ: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today...
Initial Data from Ongoing Phase 1 Trial of VIR-3434 for Chronic Hepatitis B Virus Infection Demonstrates Significant and Rapid Reduction in Hepatitis B Surface Antigen
January 26, 2021 08:00 ET
|
Vir Biotechnology, Inc.
– Novel HBV-neutralizing monoclonal antibody with therapeutic vaccine potential demonstrated a mean HBsAg reduction from baseline of 1.3 log10 IU/mL by day eight – SAN FRANCISCO, Jan. 26, 2021 ...
Vir Biotechnology and GSK Announce NHS-Supported AGILE Study to Evaluate VIR-7832 in the Early Treatment of COVID-19
January 12, 2021 03:00 ET
|
Vir Biotechnology, Inc.
Second monoclonal antibody from Vir-GSK collaboration to be investigated as a potential COVID-19 treatmentPreclinical data suggest VIR-7832 has two distinguishing properties: enhanced ability to clear...
Vir Biotechnology and GSK Announce Start of NIH-Sponsored ACTIV-3 Trial Evaluating VIR-7831 in Hospitalized Adults with COVID-19
December 17, 2020 16:01 ET
|
Vir Biotechnology, Inc.
– Randomized, placebo-controlled, multicenter, global Phase 3 trial will investigate the safety and efficacy of VIR-7831 in hospitalized adults with COVID-19 – SAN FRANCISCO and LONDON, Dec. 17,...
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2020 Financial Results
November 10, 2020 16:01 ET
|
Vir Biotechnology, Inc.
SAN FRANCISCO, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today...
Vir Biotechnology Presents New Data on VIR-2482, the Company’s Investigational Monoclonal Antibody for the Prevention of Influenza A, at IDWeek 2020
October 21, 2020 08:00 ET
|
Vir Biotechnology, Inc.
– Preclinical data show VIR-2482 has broad neutralizing potential against all major strains of influenza A from the last 100 years – – Extended half-life observed in Phase 1 demonstrates potential...
Nature Publishes New Research from Vir Biotechnology Demonstrating the Capacity of Enhanced Monoclonal Antibodies to Induce Protective Adaptive Immunity to Viral Infection
October 09, 2020 08:00 ET
|
Vir Biotechnology, Inc.
Data demonstrate potential to enhance effector function of monoclonal antibodies and induce a protective T-cell or “vaccinal” response Therapeutic approach previously applied to treatment of oncologic...
Vir Biotechnology and GSK announce global expansion to Phase 3 of COMET-ICE study evaluating VIR-7831 for the treatment of COVID-19
October 06, 2020 08:18 ET
|
Vir Biotechnology, Inc.
Independent Data Monitoring Committee recommended on September 30, 2020 that the study continue into Phase 3 based on a positive evaluation of safety and tolerability data from the Phase 2...
PAVmed Subsidiary Lucid Diagnostics Launches World-Class Medical Advisory Board and Appoints Chief Medical Officer
February 28, 2019 12:49 ET
|
PAVmed Inc.
NEW YORK, Feb. 28, 2019 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product medical device company, today announced that its...
ContraFect to Present at 18th Annual BIO CEO and Investor Conference
February 02, 2016 07:00 ET
|
ContraFect Corporation
YONKERS, NY--(Marketwired - February 02, 2016) -
ContraFect Corporation
(NASDAQ: CFRX)
(NASDAQ: CFRXW), a biotechnology company focused on the discovery and...